Evaluation of the Efficacy and Safety of Shexiang Baoxin Pill Combined with Trimexazidine in the Treatment of Coronary Heart Disease Complicated with Heart Failure
Objective:To evaluate the clinical efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine for the treatment of coronary heart disease complicated with heart failure.Methods:Computer search EMbase,the Cochrane Library,PubMed,Chinese Science and Technology Journal Database(VIP)Chinese journal service platform,Wanfang Data,China National Knowledge Infrastructure(CNKI),China Biomedical Literature Database.The retrieval time was from the establishment of the database to March 11,2022.Randomized controlled trials(RCT)of Shexiang Baoxin Pill combined with trimetazidine for the treatment of coronary heart disease complicated with heart failure were searched.The qualified literatures were screened by two researchers.Meta-analysis was performed using RevMan 5.3 software.The risk bias evaluation tool in the Cochrane review manual was used to evaluate the quality of the literature.Results:A total of 13 articles were included,involving 1 366 patients,including 683 patients in the experimental group and 683 patients in the control group.The results of Meta-analysis showed that the clinical effective rate of the experimental group was higher than that of the control group(RR=1.22,95%CI 1.15-1.28,P<0.000 01).After treatment,brain natriuretic peptide level in experimental group was lower than that in control groups(SMD=-5.06,95%CI-7.07--3.05,P<0.000 01),and left ventricular ejection fraction was higher than that in control groups(SMD=1.70,95%CI 1.36-2.04,P<0.000 01),left ventricular end-diastolic diameter(SMD=-1.31,95%CI-1.74--0.87,P<0.000 01)and left ventricular end-systolic diameter(SMD=-1.91,95%CI-2.32--1.51,P<0.000 01)were smaller than those of control group,the 6 min walking distance was higher than that of the control group(MD=48.29,95%CI 37.06-59.52,P<0.000 01),and the adverse reaction rate was lower than that of the control group(RR=0.33,95%CI 0.18-0.61,P =0.000 3).Conclusion:Available evidence shows that Shexiang Baoxin Pill and trimetazidine show synergistic effect for the treatment of CHD complicated with heart failure,they can improve the cardiac function of patients,improve clinical efficacy,and effectively reduce the incidence of adverse reactions.
NETL
NSTL
万方数据
